Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.

BACKGROUND Mammographic density and circulating sex hormones are two well-confirmed predictors of breast cancer risk. Whether mammographic density reflects levels of endogenous sex hormones is unclear. We examined whether these predictors are independently associated with breast cancer risk in a prospective study. METHODS We conducted a nested case-control study within the Nurses' Health Study cohort of 253 case subjects with breast cancer and 520 control subjects. All participants were postmenopausal women who were not using postmenopausal hormones at the time of both blood collection and mammography. Plasma levels of estradiol, free estradiol, testosterone, and free testosterone were evaluated. Mammographic density was assessed by use of computer-assisted analysis of mammograms. Logistic regression models that were adjusted for matching variables and potential confounders were used to calculate relative risks (RRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS Levels of circulating sex steroids and mammographic density were both statistically significantly and independently associated with breast cancer risk. The relative risk of breast cancer associated with mammographic density (RR for highest quartile compared with lowest quartile = 3.8, 95% CI = 2.2 to 6.6; P(trend)<.001) changed little when the analysis was adjusted for circulating estradiol (RR = 3.9, 95% CI = 2.2 to 6.9; P(trend)<.001) or circulating testosterone (RR = 4.1, 95% CI = 2.3 to 7.2; P(trend)<.001). Circulating levels of estradiol (RR = 2.4, 95% CI = 1.4 to 4.0) and of testosterone (RR = 2.0, 95% CI = 1.2 to 3.1) were both associated with breast cancer risk, before and after adjustment for mammographic density. In a joint analysis of mammographic density and plasma testosterone, the risk of breast cancer was highest in the highest tertiles of both relative to the lowest tertiles of both (RR = 6.0, 95% CI = 2.6 to 14.0). A similar pattern was observed in the joint analysis of estradiol and mammographic density (RR = 4.1, 95% CI = 1.7 to 9.8). CONCLUSIONS Circulating sex steroid levels and mammographic density appear strongly and independently associated with the risk of breast cancer in postmenopausal women.

[1]  I. Gram,et al.  Percentage density, Wolfe's and Tabár's mammographic patterns: agreement and association with risk factors for breast cancer , 2005, Breast Cancer Research.

[2]  C. Streuli,et al.  Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function , 2002, Breast Cancer Research.

[3]  I. Helenowski,et al.  Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. , 2005, The Journal of clinical endocrinology and metabolism.

[4]  M. Dowsett,et al.  Deficits in plasma oestradiol measurement in studies and management of breast cancer , 2004, Breast Cancer Research.

[5]  Stephen W Duffy,et al.  Tamoxifen and breast density in women at increased risk of breast cancer. , 2004, Journal of the National Cancer Institute.

[6]  Navin Parekh,et al.  Effects of mammographic density and benign breast disease on breast cancer risk (United States) , 2001, Cancer Causes & Control.

[7]  M. Pike,et al.  The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. , 2005, American journal of epidemiology.

[8]  A. Miller,et al.  Mammographic densities and the prevalence and incidence of histological types of benign breast disease , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[9]  N F Boyd,et al.  Symmetry of projection in the quantitative analysis of mammographic images , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[10]  B. V. VON Schoultz,et al.  Mammographic breast density during hormone replacement therapy: differences according to treatment. , 1999, American journal of obstetrics and gynecology.

[11]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[12]  R. Osathanondh,et al.  The microenvironment of the human antral follicle: interrelationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro. , 1979, The Journal of clinical endocrinology and metabolism.

[13]  G. Secreto,et al.  Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  N F Boyd,et al.  The association of breast mitogens with mammographic densities , 2002, British Journal of Cancer.

[15]  R. J. Marshall,et al.  Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. , 1985, Statistics in medicine.

[16]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[17]  L. Esserman,et al.  Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis , 2005, Breast Cancer Research.

[18]  G. Colditz,et al.  Endogenous Sex Hormone Levels and Mammographic Density among Postmenopausal Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[19]  I Persson,et al.  Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Speizer,et al.  Characteristics of respondents and non-respondents to a mailed questionnaire. , 1980, American journal of public health.

[21]  J. Brisson,et al.  Tamoxifen and mammographic breast densities. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  S. Cummings,et al.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.

[23]  A. Miller,et al.  Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.

[24]  Jinbo Chen,et al.  Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.

[25]  B. Rosner,et al.  Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer , 2004, Cancer Research.

[26]  D. Venzon,et al.  Effect of tamoxifen on mammographic density. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[28]  M. Ferin,et al.  Radioimmunoassay of plasma estrone and estradiol. , 1970, Steroids.

[29]  S. Khan,et al.  The local hormonal environment and related biomarkers in the normal breast. , 2005, Endocrine-related cancer.

[30]  Karla Kerlikowske,et al.  Prospective breast cancer risk prediction model for women undergoing screening mammography. , 2006, Journal of the National Cancer Institute.

[31]  S. Hankinson,et al.  Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. , 2004, Journal of the National Cancer Institute.

[32]  W. Willett,et al.  Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. , 2000, Cancer research.

[33]  P. Porter,et al.  Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. , 2000, Journal of the National Cancer Institute.

[34]  C. Y. Wang,et al.  Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. , 2005, Journal of the National Cancer Institute.

[35]  C. Herman,et al.  Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. , 1997, Journal of the National Cancer Institute.

[36]  David Tritchler,et al.  Heritability of mammographic density, a risk factor for breast cancer. , 2002, The New England journal of medicine.

[37]  K. Kerlikowske,et al.  Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System. , 1998, Journal of the National Cancer Institute.

[38]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[39]  F. Stanczyk.  Measurement of androgens in women. , 2006, Seminars in reproductive medicine.

[40]  A. Morrison,et al.  Endogenous sex hormones, prolactin, and mammographic features of breast tissue in premenopausal women. , 1986, Journal of the National Cancer Institute.

[41]  B. Rosner.  Percentage Points for a Generalized ESD Many-Outlier Procedure , 1983 .

[42]  J. Chang-Claude,et al.  Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. , 2005, Endocrine-related cancer.

[43]  S. Bustin,et al.  The GH–IGF-I axis and breast cancer , 2003, Trends in Endocrinology & Metabolism.

[44]  M. Ferin,et al.  Radioimmunoassay of Plasma Estrogens: Use of Polymerized Antibodies , 1970 .

[45]  S. Cummings,et al.  Mammographic density and estrogen receptor status of breast cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  L. Liberman,et al.  Breast imaging reporting and data system (BI-RADS). , 2002, Radiologic clinics of North America.

[47]  B. Reboussin,et al.  Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study , 2005, Breast Cancer Research.

[48]  W. Willett,et al.  Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). , 2006, Journal of the National Cancer Institute.

[49]  R. Shore,et al.  Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study , 2004, British Journal of Cancer.

[50]  P. Stomper,et al.  Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. , 1990, Radiology.

[51]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[52]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[53]  Beth A Reboussin,et al.  Postmenopausal hormone therapy and change in mammographic density. , 2003, Journal of the National Cancer Institute.

[54]  J. Wolfe,et al.  Mammographic features and breast cancer risk: effects with time, age, and menopause status. , 1995, Journal of the National Cancer Institute.

[55]  G. Maskarinec,et al.  Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. , 2006, Breast.

[56]  B. Geller,et al.  A prospective study of breast cancer risk using routine mammographic breast density measurements. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[57]  R. Horton,et al.  A specific radioimmunossay for testosterone in peripheral plasma. , 1973, The Journal of laboratory and clinical medicine.

[58]  N Houssami,et al.  Reader variability in reporting breast imaging according to BI-RADS assessment categories (the Florence experience). , 2006, Breast.

[59]  T. Bäckström,et al.  Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. , 1982, Journal of steroid biochemistry.

[60]  F. Berrino,et al.  Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[61]  B. Zee,et al.  Mammographic density in women on postmenopausal hormone replacement therapy , 1997 .

[62]  Celine M Vachon,et al.  Case-control study of increased mammographic breast density response to hormone replacement therapy. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  J. Deslypere,et al.  Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. , 1986, European journal of cancer & clinical oncology.

[64]  S. Ciatto,et al.  Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. , 2005, Breast.

[65]  D. Spiegelman,et al.  Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. , 2006, Journal of the National Cancer Institute.

[66]  S. Korenman,et al.  Chromatographic purification of estradiol-17 for use in radio-ligand assay. , 1970, Biochemical medicine.

[67]  S. Cummings,et al.  Are breast density and bone mineral density independent risk factors for breast cancer? , 2005, Journal of the National Cancer Institute.

[68]  G. Colditz,et al.  Association of age and reproductive factors with benign breast tissue composition. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[69]  Graham A. Colditz,et al.  The Nurses' Health Study: lifestyle and health among women , 2005, Nature Reviews Cancer.

[70]  Robert J Cersosimo,et al.  Tamoxifen for Prevention of Breast Cancer , 2003 .

[71]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[72]  S. Cummings,et al.  Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population , 2005, Breast Cancer Research and Treatment.